Top Page
Modalis Therapeutics Corporation
(4883)
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Modalis Therapeutics Corporation Business Overview & Revenue Model
Modalis Therapeutics Corporation Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 40.50M | 1.10M |
| Gross Profit | -583.00K | 0.00 | 0.00 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.33B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -1.56B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.42B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.26B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 0.00 | 0.00 | 0.00 | 412.50M | 0.00 | 0.00 |
| Total Liabilities | 228.82M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 3.19B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0.00 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0.00 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0.00 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Modalis Therapeutics Corporation Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥15.83B | 17.20 | ― | ― | -5.41% | ― | |
64 Neutral | ¥6.42B | 11.77 | ― | 3.21% | 4.25% | ― | |
52 Neutral | ¥9.64B | -1.70 | ― | ― | -50.27% | -3.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥10.10B | -9.94 | -90.96% | ― | 243.16% | -23.00% | |
48 Neutral | ¥6.66B | -7.70 | ― | ― | 56.17% | -11.63% | |
41 Neutral | ¥5.16B | -2.12 | ― | ― | ― | 47.43% |
Modalis Therapeutics Corporation Corporate Events
Modalis Therapeutics reported continued progress in preparing its lead candidate MDL-101 for clinical trials, citing consistent survival benefits in disease model mice and no new safety concerns, while conducting further analyses to refine development parameters. The company emphasized that these activities are intended to strengthen translational robustness and execution certainty, rather than reflecting any change in the underlying therapeutic concept.
As part of a disciplined, data-driven approach, Modalis is reassessing the timing of its planned IND submission for MDL-101 and signaled that the application could be delayed beyond the original schedule to ensure optimal clinical readiness. Management stressed that the optimization efforts are specific to MDL-101 and do not indicate broader issues with the CRISPR-GNDM platform or the rest of the pipeline.
In parallel, Modalis has reached a term sheet-level strategic understanding with a third party for regional clinical development and future commercialization rights, providing external validation of MDL-101’s potential and supporting its global strategy. The company is also evaluating possible impacts on its financial forecasts, while continuing regulatory dialogue and planning further disclosures as program milestones are clarified.
The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.
Modalis Therapeutics has reported a widening loss for the fiscal year ended December 31, 2025, with consolidated operating income falling to a deficit of ¥2,211 million and profit attributable to owners of the parent deepening to a loss of ¥2,152 million. The company again posted no operating revenue, underscoring its status as a pre-commercial R&D-driven biotech.
On a non-consolidated basis, operating income deteriorated to a loss of ¥2,302 million and net profit to a loss of ¥2,249 million, though the per-share loss narrowed slightly to ¥29.11. Management attributed the larger losses across both consolidated and non-consolidated results to higher research and development expenses, highlighting an aggressive investment stance that could weigh on near-term earnings while aiming to support longer-term pipeline progress.
The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.
Modalis Therapeutics Corporation reported non-operating income of ¥10 million in foreign exchange gains for the fiscal year ended December 31, 2025, driven mainly by the revaluation of its foreign currency-denominated assets and liabilities amid exchange rate fluctuations. The company indicated that the detailed impact of these foreign exchange gains and any related extraordinary losses on its overall earnings is reflected in its consolidated financial results for the same fiscal year, underscoring how currency movements continue to influence its financial performance.
While the reported foreign exchange income is relatively modest in absolute terms, it highlights the company’s financial sensitivity to exchange rate volatility stemming from its international exposure. Stakeholders are directed to the latest consolidated results for a fuller picture of profitability and risk, suggesting that foreign currency effects are an ongoing factor in assessing Modalis Therapeutics’ earnings stability.
The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.
Modalis Therapeutics Corporation released an English reference version of its business and financial report for the fiscal year ending in 2025, dated February 12, 2026, clarifying that the Japanese version remains the authoritative document. The company emphasizes that the materials are for informational purposes only, are confidential, and may not be reproduced or redistributed without prior written consent, underscoring tight control over the dissemination of its financial and operational disclosures.
The report includes a detailed disclaimer that it does not constitute an offer or solicitation to buy or sell securities in Japan, the U.S. or elsewhere and that the information may change without notice. Modalis further notes that any forward-looking statements are subject to significant risks and uncertainties, disclaims responsibility for third‑party data included, and explicitly rejects any obligation to update or correct the information, signaling a cautious stance toward investor expectations and legal exposure.
The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.
Modalis Therapeutics reported no operating revenue for the fiscal year ended December 31, 2025, and widened its consolidated loss, with operating income at a loss of ¥2,211 million and profit attributable to owners of parent at a loss of ¥2,152 million. Total assets fell to ¥2,964 million from ¥3,691 million, equity declined, and cash and cash equivalents decreased to ¥2,812 million as operating cash outflows grew, although financing activities partially offset this.
The company maintained a no-dividend policy for 2024 and 2025 and forecasts no dividend for 2026, underscoring its focus on reinvesting capital into operations. Modalis did not provide earnings forecasts for fiscal 2026, citing difficulty in making reasonable estimates, which highlights the uncertainty typical of early-stage biotech firms and leaves investors with limited visibility on the timing of future revenue or profitability.
The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.